Related references
Note: Only part of the references are listed.Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study
Joan L. Walker et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
K. Moore et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
OV21/PETROC: a randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer
D. M. Provencher et al.
ANNALS OF ONCOLOGY (2018)
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Robert L. Coleman et al.
LANCET (2017)
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
Eric Pujade-Lauraine et al.
LANCET ONCOLOGY (2017)
Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial
Robert L. Coleman et al.
LANCET ONCOLOGY (2017)
Niraparib in Recurrent Ovarian Cancer
Alison M. Schram et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions
A. Karam et al.
ANNALS OF ONCOLOGY (2017)
Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer
J. K. Chan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial
Amit M. Oza et al.
LANCET ONCOLOGY (2015)
Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial
Sandro Pignata et al.
LANCET ONCOLOGY (2014)
BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study
J. L. Lesnock et al.
BRITISH JOURNAL OF CANCER (2013)
Principle and evolving role of intraperitoneal chemotherapy in ovarian cancer
Keiichi Fujiwara et al.
EXPERT OPINION ON PHARMACOTHERAPY (2013)
Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial
Noriyuki Katsumata et al.
LANCET ONCOLOGY (2013)
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
Jonathan Ledermann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
A Randomized Phase II/III Trial of 3 Weekly Intraperitoneal versus Intravenous Carboplatin in Combination with Intravenous Weekly Dose-dense Paclitaxel for Newly Diagnosed Ovarian, Fallopian Tube and Primary Peritoneal Cancer
Keiichi Fujiwara et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2011)
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Robert A. Burger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
A Phase 3 Trial of Bevacizumab in Ovarian Cancer
Timothy J. Perren et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Principles and practice of intraperitoneal chemotherapy for ovarian cancer
K. Fujiwara et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2007)
Share Paper
